The CAH StripAssay® offered by Oasis Diagnostics Corporation is a cost effective tool for the confirmation of Congenital Adrenal Hyperplasia (CAH) early in the disease cycle to to minimize emotional stress for parents and economic burden. Neonatal 17-OHP testing is highly susceptible to false positive results, making genetic testing an important confirmatory tool for early and reliable CAH diagnosis. The CAH StripAssay® is based on detection of the CYP21A2 gene in dry blood samples.
CAH StripAssay® Catalog 4-380
I2 splice (I2 G)
Del 8 bp E3 (G110del8nt)
Cluster E6 (I236N, V237E, M239K)
L307 frameshift (F306+T)